Founded

Address

Clarus Ventures LLC
One Memorial Drive
Suite 1230
Cambridge, MA 02142
United States

Open map


Recent investment activity

KANDO id: 30972

Corporate information

Official name
Clarus Ventures LLC
Registration country

Company type

Life sciences venture capital firm

Funds managed

Fund Type Vintage Currency Committed capital IRR x
Clarus IV-A LP Venture 2017 USD 789,700,000
Clarus IV-B LP Venture 2017 USD 789,700,000
Clarus IV-C LP Venture 2017 USD 789,700,000
Clarus IV-D LP Venture 2017 USD 789,700,000
Clarus DE II LP Venture 2014 USD 40,000,000
Clarus Defined Exit I LP Venture 2014 USD 100,000,000
Clarus Lifesciences III LP Venture 2014
Clarus Ventures III GP LP Venture 2014
Clarus Lifesciences II LP Venture 2008 USD 14.80 % 1.80 x
Clarus Lifesciences I LP Venture 2006 USD 3.90 % 1.20 x
Clarus Ventures II Venture USD 697,000,000

Funding rounds

Profile Country Notes
The Blackstone Group LP Private equity firm Led the round.


Investment activity status
Not investing

Selected investments

Displaying 1 - 20 of 38
Profile Country Date Funding
Avanir Pharmaceuticals Inc A biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. N/A
Catabasis Pharmaceuticals Inc Series A
Catabasis Pharmaceuticals Inc Series A
Cellerant Therapeutics Inc Biotechnology company with a portfolio of products based on the regulation of the hematopoietic (blood-forming) system. N/A
CoMentis Inc N/A
Delenex Therapeutics AG N/A
Edev N/A
ESBATech AG Switzerland based Biomedical Research Unit of Alcon Series B
ESBATech AG Switzerland based Biomedical Research Unit of Alcon Series B
FerroKin Biosciences Inc A clinical stage biotechnology company dedicated to improving the management of patients with iron overload. N/A
Flowonix Medical A medical device company dedicated to helping those who suffer from chronic disorders. N/A
Globus Medical Inc A medical device company, focuses on the design, development, and commercialization of products that promote healing in patients with spine disorders. Series E
Heptares Therapeutics Ltd Series A
Link Medicine Inc Advancing disease-modifying technologies targeted at Alzheimer's, Parkinson's and other neurodegenerative diseases Series C
Lycera Corp Series A
Pearl Therapeutics Inc Developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases N/A
Pearl Therapeutics Inc Developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases N/A
Proacta Inc Series B
SARcode Bioscience Inc Series B
Sientra Inc Medical device company Series C

Current employees

Financials